Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Lopes, EA (Author) Other; Gomes, S (Author) Other; Lucilia Saraiva (Author) FFUP; Santos, MMM (Author) Other

Journal

Title: Current Medicinal Chemistry

Vol. 26

Pages: 7323-7336

ISSN: 0929-8673

Publisher: Bentham

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-00R-KE4

DOI: 10.2174/0929867325666181116124308

Abstract (EN): More than half of all human tumors express mutant forms of p53, with the ovary, lung, pancreas, and colorectal cancers among the tumor types that display the highest prevalence of p53 mutations. In addition, the expression of mutant forms of p53 in tumors is associated with poor prognosis due to increased chemoresistance and invasiveness. Therefore, the pharmacological restoration of wild-type-like activity to mutant p53 arises as a promising therapeutic strategy against cancer. This review is focused on the most relevant mutant p53 small molecule reactivators described to date. Despite some of them have entered into clinical trials, none has reached the clinic, which emphasizes that new pharmacological alternatives, particularly with higher selectivity and lower adverse toxic side effects, are still required.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14